Drug Profile
Research programme: immuno-oncology therapeutics - Pieris Pharmaceuticals/Seagen
Alternative Names: Research programme: antibody-Anticalin fusion proteins - Pieris Pharmaceuticals/SeagenLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Pieris Pharmaceuticals; Seattle Genetics
- Developer Pieris Pharmaceuticals; Seagen
- Class Antibodies; Antineoplastics; Immunotherapies; Lipocalins; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours